Observations placeholder

Mitoxantrone (INN, BAN, USAN; also known as Mitozantrone in Australia; trade name Novantrone) is an anthracenedione antineoplastic agent.

Uses

Mitoxantrone is used in the treatment of certain types of cancer, mostly metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's lymphoma. It is also used for children suffering from first relapse of acute lymphoblastic leukemia

The combination of mitoxantrone and prednisone is also used as a second-line treatment for metastatic hormone-refractory prostate cancer.

Mitoxantrone is also used to treat multiple sclerosis (MS), most notably the subset of the disease, known as secondary-progressive MS. As no cure for multiple sclerosis exists yet, it must be understood mitoxantrone will not cure the disease, but is used in slowing the progression of secondary-progressive MS and extending the time between relapses in both relapsing-remitting MS and progressive-relapsing MS.

Side effects

Mitoxantrone, as other drugs in its class, may cause several adverse reactions of varying severity, such as nausea, vomiting, hair loss, heart damage, and immunosuppression, which may also have a delayed onset. Cardiomyopathy is a particularly concerning effect as it is irreversible; thus regular monitoring with echocardiograms or MUGA scans is recommended for people taking mitoxantrone.

Because of the risk of cardiomyopathy, mitoxantrone carries a limit on the cumulative lifetime dose (based on body surface area) in patients with multiple sclerosis

On Jan, 21, 2016: 3,010 people reported to have side effects when taking Novantrone. Among them, 2 people (0.07%) have Hallucination.

Time on Novantrone when people have Hallucination :

 On Dec, 28, 2015: 3,010 people reported to have side effects when taking Novantrone. Among them, 52 people (1.73%) have Death.

Time on Novantrone when people have Death  :

Age of people who have Death when taking Novantrone  :

Top conditions involved for these people  :

1. Multiple sclerosis (21 people, 40.38%)
2. Prostate cancer metastatic (3 people, 5.77%)
3. Osteoporosis (3 people, 5.77%)